Table II.
Demographics, clinical characteristics, and outcomes of 171 children with COVID-19 following vaccination
| Variables | Total infections following vaccination, n (%) (N = 171) | Pre-Omicron, n (%) (N = 25) | Omicron, n (%) (N = 146) | P value |
|---|---|---|---|---|
| Age, y, median (IQR) | 14 (12-16) | 16 (13-17) | 14 (12-16) | .0022 |
| Days between vaccination∗ and infection, median (IQR) | 160 (76-186) | 116 (95-163) | 167.5 (40-187) | .0382 |
| Sex (male), n (%) | 90 (52.6) | 15 (60) | 75 (51.4) | .517 |
| Race (Black), n (%) | 31 (18.1) | 0 (0) | 31 (21.2) | .071 |
| Ethnicity (Hispanic), n (%) | 56 (32.8) | 10 (40) | 46 (31.5) | .676 |
| Comorbid condition for COVID-19 complications (any), n (%) | 89 (52.1) | 11 (44) | 78 (53.4) | .397 |
| Cardiac | 10 (5.9) | 0 (0) | 10 (6.9) | .361 |
| Respiratory | 38 (22.2) | 3 (12) | 35 (24) | .296 |
| Immunodeficiency | 18 (10.5) | 2 (8) | 16 (10.9) | 1.00 |
| Diabetes | 4 (2.3) | 0 (0) | 4 (2.7) | 1.00 |
| Obesity | 35 (20.5) | 6 (24) | 29 (19.9) | .163 |
| COVID vaccine type (Pfizer-BioNTech), n (%) | 167 (97.7) | 24 (96) | 143 (98) | .472 |
| Received booster dose, n (%) | 5 (2.9) | 0 (0) | 5 (3.4) | 1.00 |
| Received third dose because of immunodeficiency, n (%) | 1 (0.6) | 1 (4) | 0 (0) | .146 |
| Viral coinfection†, n (%) | 1 (0.6) | 0 (0) | 1 (0.7) | 1.00 |
| Symptoms of COVID-19 (any), n (%) | 151 (88.3) | 17 (68) | 134 (91.8) | .003 |
| Fever | 50 (29.2) | 7 (28) | 43 (29.5) | 1.00 |
| Upper respiratory infection symptoms | 60 (35.1) | 9 (36) | 51 (34.9) | 1.00 |
| Loss of taste and/or smell | 3 (1.8) | 0 (0) | 3 (2.1) | 1.00 |
| Cough | 54 (31.6) | 5 (20) | 49 (33.6) | .245 |
| Shortness of breath | 10 (5.9) | 0 (0) | 10 (6.9) | .361 |
| Sore throat | 56 (32.8) | 5 (20) | 51 (34.9) | .171 |
| Gastrointestinal symptoms | 20 (11.7) | 0 (0) | 20 (13.7) | .047 |
| Headache | 30 (17.5) | 4 (16) | 26 (17.8) | 1.00 |
| Other | 45 (26.3) | 3 (12) | 42 (28.8) | .089 |
| Hospitalized for COVID-19‡, n (%) | 4 (2.3) | 0 (0) | 4 (2.7) | 1.00 |
| COVID-19 pharmacologic treatment, n (%) | 2 (1.2) | 1 (4) | 1 (0.7) | .272 |
| Monoclonal antibodies§, n (%) | 1 (0.6) | 1 (4) | 0 (0) | .146 |
| Remdesivir | 1 (0.6) | 0 (0) | 1 (0.7) | 1.00 |
| Corticosteroids | 1 (0.6) | 0 (0) | 1 (0.7) | 1.00 |
| COVID-19 severity score, n (%) | ||||
| Mild (1-2) | 165 (96.5) | 25 (100) | 140 (95.9) | .594 |
| Moderate (3-5) | 6 (3.5) | 0 (0) | 6 (4.1) |
Bold P values denote statistical significance.
∗
Day 1 starts 14 days after completing primary vaccine series.
†
The single viral coinfection was rhinovirus/enterovirus.
‡
No patients required respiratory support or intensive care.
§
Specific monoclonal antibody unavailable; patient received at outside location.